This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)
by Zacks Equity Research
DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study
by Zacks Equity Research
The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.
Kymera Therapeutics, Inc. (KYMR) Moves 9.6% Higher: Will This Strength Last?
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold
by Zacks Equity Research
DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
NGM Biopharmaceuticals (NGM) Soars 6.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Is Lantheus (LNTH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.
Down 42.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)
by Zacks Equity Research
DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down 36.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)
by Zacks Equity Research
DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
New Strong Sell Stocks for January 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for January 13th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
DBV Technologies is in Overbought Territory: What???s Next?
by Zacks Equity Research
DBV Technologies has moved higher as of late, but there could definitely be trouble on the horizon for this company.
DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DBV Technologies S.A. (DBVT) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in DBV Technologies S.A. (DBVT).
Implied Volatility Surging for DBV Technologies (DBVT) Stock Options
by Zacks Equity Research
DBV Technologies (DBVT) needs investors to pay close attention to the stock based on moves in the options market lately.
DBV Technologies (DBVT) Worth a Look: Stock Up 5.7%
by Zacks Equity Research
DBV Technologies S.A. (DBVT) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Is DBV Technologies (DBVT) Stock a Solid Choice Right Now?
by Zacks Equity Research
DBV Technologies (DBVT) in the Medical-Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.